Slide Source: Lipids Online Slide Library www.lipidsonline.org Prospective Pravastatin Pooling Project: Coronary Event Rates in CARE and LIPID Patients.

Slides:

Advertisements

Similar presentations

1 Baseline BMI and Age-Adjusted Incidence of Diabetes Mellitus White Men Level of BMI Percent

Advertisements

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)

1 SECOND AUSTRALIAN NATIONAL BLOOD PRESSURE STUDY (ANBP-2) Enalapril/ACEI vs. HCTZ, n = 6,083 Randomized, open-label (blinded endpoint review) All CV events.

OBESITY and CHD Nathan Wong. OBESITY AHA and NIH have recognized obesity as a major modifiable risk factor for CHD Obesity is a risk factor for development.

TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.

Lipid Disorders and Management in Diabetes

Slide Source LipidsOnline CO O C CH 3 COOCH CH 3 Cl CH 3 OC COOC 2 H 5 CH 3 Cl CH 3 OCH 2 CH 3 COOH CH 3 C Fenofibrate Clofibrate.

Slide Source: Lipids Online Slide Library 56 healthy premenopausal obese women (aged 25–44 years) compared with 40 age-matched nonobese.

Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.

Slide Source: Lipids Online Slide Library High-Density Lipoprotein and the Epidemiology of Coronary Heart Disease Michael Miller,

The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:

Slide Source: Lipids Online Slide Library Heart and Estrogen/progestin Replacement Study (HERS) and HERS II: Secondary Prevention.

Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.

TC LDL- C HDL- C Nonfatal MI/CHD death CHD death All- cause mortality *As compared to placebo. † P= CARE: Effect of Lipid Lowering on Lipid Values.

LIPID LOWERING IN T2D (The Lower the Better?) CONS… TARGETING HARD CVD END POINTS Charles SAAB MD Consultant Endocrinologist DCRP Sacre-Coeur University.

TM © 1999 Professional Postgraduate Services ® S: Total Mortality Reduction in a Subgroup of Patients With Diabetes Proportion.

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Ungroup once.

Simvastatin in Patients With Prior Cerebrovascular Disease: HPS

(N=488) Simvastatin in Patients With Prior Cerebrovascular Disease: HPS *29% RRR, p=0.001 Heart Protection Study Collaborative Group. Lancet. 2004;363:

Metabolic Syndrome, Diabetes, and Cardiovascular Disease: Implications for Preventive Cardiology Nathan D. Wong, PhD, FACC, FAHA Professor and Director.

Slide Source: Lipids Online Plasma Concentration of TNF- and Risk of Recurrent Coronary Events –2.47 (1 st –50 th.

Factors That Increase the Risk of Myopathy in People Taking Statins Philip J. Barter, and Kerry-Anne Rye Circulation 2006;114: ) Jones PH, Davidson.

ASTEROID A Study To evaluate the Effect of Rosuvastatin On Intravascular ultrasound- Derived coronary atheroma burden.

HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.

Slide Source: Lipids Online Slide Library Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)

Slide Source: Lipids Online Slide Library Women’s Health Initiative: Trial of Estrogen plus Progestin 16,608 women randomized 16,608.

1. Relation between dietary macronutrient and fiber intake with metabolic syndrome in Tehranian adults: Tehran Lipid and Glucose Study Hosseinpour S,

BackgroundBackground HDL-C levels are inversely related to CV event rates. HDL-C levels are inversely related to CV event rates. Torcetrapib, a cholesteryl.

Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.

Slide Source: Lipids Online Slide Library Collaborative Atorvastatin Diabetes Study (CARDS) Type 2 diabetes mellitus Men and women.

Bezafibrate Infarction Prevention Trial (BIP) Results Presented at the European Society of Cardiology Meeting Vienna, Austria 1998.

Pai JK et al. N Engl J Med 2004; 351: Relative CHD risk by increasing baseline CRP plasma levels,* relative to CRP

Ho PM, et al. JAMA 2009;301: Baseline Characteristics of Patients Taking Clopidogrel After Hospital Discharge a Ho PM, et al. JAMA 2009;301:

The Prospective Pravastatin Pooling Project L I P I D CARECARE PPP Project Investigators Am J Cardiol 1995; 76:899–905.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J, Pyorala K for the 4S Group Reduced Coronary Events in Simvastatin-Treated.

AA-2-1 Jerome D. Cohen, MD, FACC, FACP Professor of Internal Medicine / Cardiology Director, Preventive Cardiology Programs St. Louis University Health.

VBWG PROactive: Study design Dormandy JA et al. Lancet. 2005;366: Charbonnel B et al. Diabetes Care. 2004;27: Objective: Assess the effects.

Clinical Trial Results. org SAGE Trial Prakash Deedwania, MD; Peter H. Stone, MD; C. Noel Bairey Merz, MD; Juan Cosin-Aguilar, MD; Nevres Koylan, MD; Don.

VBWG Predictor of CV Events and Mortality in Postmenopausal Women: Leukocyte Count.

A Diabetes Outcome Progression Trial

Enrollment, Randomization, and Follow-up of Study Participants ADVANCE Collaborative Group. N Engl J Med 2008;358:

Slide Source: Lipids Online Slide Library LDL Cholesterol, mg/dL Years of Follow-up Ridker PM et al. N Engl J Med 2002;347:1557–1565.

Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.

Slide Source: Lipids Online Slide Library ASTEROID Population at Baseline (n=507) Patients Completing (n=349) Patients Not Completing.

Diabetes Prevention Program (DPP)

Diabetes and Cause-Specific Mortality in a Prospective Cohort of One Million U.S. Adults Featured Article: Peter T. Campbell, Ph.D., Christina C. Newton,

Slide Source: Lipids Online Slide Library C-Reactive Protein, Metabolic Syndrome, and Risk for CV Events: Women’s Health Study 14,719.

Slide Source: Lipids Online Slide Library Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Design Sever PS et al. J Hypertens 2001;19:1139–1147.

Slide Source Kaplan-Meier Curve of Time to Primary End Point Proportion of Events (%) Pioglitazone Placebo PROactive investigators.

The FIRST Trial: A Rationale Davidson M, Rosenson RS, Maki KC et al. Study design, rationale, and baseline characteristics: evaluation of fenofibric acid.

Predictive value of CRP vs LDL-C (i) Ridker PM, et al. N Engl J Med 2002;347: Quintile of CRP (mg/L)

Slide Source: Lipids Online Slide Library Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Nissen SE et al. JAMA.

Unnecessary Lipid Screening of Inpatient Admissions Dennis Whang 4/2/12 DSR2.

Comparison of baseline characteristics in participants who subsequently had an incident cardiovascular event or new-onset diabetes in the Prospective.

Copyright © 2012 American Medical Association. All rights reserved.

Description of studies for pooled analyses

Baseline Characteristics

Baseline Characteristics According to Sex

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

Baseline Lipid Parameters and Characteristics Among 3110 Men According to Quintiles of Total Cholesterol Ruben O. Halperin et al, Hypertension 2006;47;45-50.

Baseline Characteristics by hs-CRP

PROSPER: trial design

Baseline characteristics of the 1,842 men without coronary heart disease and the 230 men with a first coronary heart disease event during the 13-year.

Adjusted HRs (95% CIs) for all-cause mortality associated with BMI by smoking status in men and women and by CHD, type 2 diabetes, and cancer status at.

The prevalence of type 2 diabetes for R1420H carriers and noncarriers in relation to BMI. Diabetes prevalence is shown in individuals stratified by their.

Adjusted HRs (95% CIs) for all-cause mortality associated with body fat percentage by smoking status in men and women and by CHD, type 2 diabetes, and.

Example of how quantitative variables displaying a nonhomogeneous risk in visual display were split in high- and low-risk categories. Example of how quantitative.

RR (with 95% CI) of total mortality (multivariate-adjusted) by duration of smoking cessation among diabetic women. RR (with 95% CI) of total mortality.

Presentation transcript:

Slide Source: Lipids Online Slide Library Prospective Pravastatin Pooling Project: Coronary Event Rates in CARE and LIPID Patients with Baseline LDL-C <125 mg/dL Characteristic Coronary events/total patients (%) RR (95% CI) Pravastatin(n=1316)Placebo(n=1291) Age 60 y 178/790 (23) 187/788 (24) 0.96 (0.78–1.17) Age <60 y 106/526 (20) 105/503 (21) 0.96 (0.74–1.26) Women 26/170 (15) 30/147 (20) 0.74 (0.44–1.26) Men 258/1146 (23) 262/1144 (23) 0.98 (0.83–1.17) HTN 138/549 (25) 158/594 (27) 0.94 (0.75–1.18) No HTN 146/767 (19) 134/697 (19) 0.99 (0.79–1.26) Diabetes 39/181 (22) 65/189 (34) 0.56 (0.37–0.83)* No diabetes 245/1135 (22) 227/1102 (21) 1.06 (0.89–1.27) *p=.004; p=.005 for interaction Sacks FM et al. Circulation 2002;105:

Slide Source: Lipids Online Slide Library Prospective Pravastatin Pooling Project: Coronary Event Rates in CARE and LIPID Patients with Baseline LDL-C <125 mg/dL Characteristic Coronary events/total patients (%) RR (95% CI) Pravastatin(n=1316)Placebo(n=1291) BMI 27 kg/m 2 147/612 (24) 154/596 (26) 0.92 (0.73–1.15) BMI <27 kg/m 2 136/702 (19) 137/693 (20) 0.98 (0.77–1.24) HDL-C <40 mg/dL 217/945 (23) 240/900 (27) 0.84 (0.70–1.01)* HDL-C 40 mg/dL 67/371 (18) 52/391 (13) 1.42 (0.99–2.04) TG 150 mg/dL 160/638 (25) 159/626 (25) 0.98 (0.79–1.23) TG <150 mg/dL 124/678 (18) 133/665 (20) 0.91 (0.71–1.17) Smoking 24/123 (20) 40/137 (29) 0.63 (0.38–1.05)† Nonsmoking 260/1193 (22) 252/1154 (22) 1.00 (0.84–1.19) *p=.06 for RR in HDL-C groups and for interaction (HDL-C as continuous variable) †p=0.075; p=.09 for interaction Sacks FM et al. Circulation 2002;105:

Slide Source: Lipids Online Slide Library >60 Coronary Event Rate (%) Sacks FM et al. Circulation 2002;105: Prospective Pravastatin Pooling Project: Coronary Event Rates in CARE and LIPID Patients with Baseline LDL-C <125 mg/dL <60FM+—+—+—>27<27<40>40 >150<150 AgeSexHTNSmokingDMBMIHDL-CTG ** * Pravastatin Placebo *p=.004 *p=.004 **p (interaction) =.005

Slide Source: Lipids Online Slide Library Cumulative Coronary Event Rates in Diabetic and Nondiabetic Patients with Baseline LDL-C <125 mg/dL Cumulative Risk of Coronary Event or Procedure (%) Years Follow-up Sacks FM et al. Circulation 2002;105: Placebo Diabetic Pravastatin Nondiabetic Pravastatin Diabetic Placebo Nondiabetic